Nephrotoxicity of conventional chemotherapeutics: part 1—platinum compounds and antimetabolite agents

Anticancer therapies have significantly improved survival rates in patients with cancer; however, despite prophylactic measures, many conventional chemotherapeutic agents cause acute and chronic kidney injury. This review provides a comprehensive analysis of the incidence, characteristics, and management of platinum-based and anti-metabolite chemotherapeutic agent-associated nephrotoxicity based on the existing literature. Understanding the profiles of these onconephrotoxic agents is essential for optimizing anticancer treatment while minimizing kidney complications.

Authors

Institutions

Publication Details

Journal
Nephrology Dialysis Transplantation
Published
2025-11-15
DOI
https://doi.org/10.1093/ndt/gfaf251
Primary Topic
Chemotherapy-induced organ toxicity mitigation
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Nephrotoxicity of conventional chemotherapeutics: part 1—platinum compounds and antimetabolite agents

Adam Kelly, Omar Mamlouk, Kenar D. Jhaveri, Kartik Kalra et al.
Nephrology Dialysis Transplantation
Chemotherapy-induced organ toxicity mitigation
article

Nephrotoxicity of conventional chemotherapeutics: part 1—platinum compounds and antimetabolite agents

Adam Kelly, Omar Mamlouk, Kenar D. Jhaveri, Kartik Kalra, Tanazul T. Pariswala, Sylvia S Eskander, Sourabh Sharma, Mark A. Perazella, Shruti Gupta, Marco A. Bonilla, Mohamed Ibrahim, Prakash Gudsoorkar, Paul E. Hanna, Mohamed Hassanein, Anna-Eve Turcotte, Munjal Patel, Raad B. Chowdhury, Carl Dernell, Rimda Wanchoo, Ishaan Zaveri, Heather Troung
article en

Abstract

Anticancer therapies have significantly improved survival rates in patients with cancer; however, despite prophylactic measures, many conventional chemotherapeutic agents cause acute and chronic kidney injury. This review provides a comprehensive analysis of the incidence, characteristics, and management of platinum-based and anti-metabolite chemotherapeutic agent-associated nephrotoxicity based on the existing literature. Understanding the profiles of these onconephrotoxic agents is essential for optimizing anticancer treatment while minimizing kidney complications.

Nephrology Dialysis Transplantation
Brigham and Women's Hospital (US), Northeastern University (US), Geisinger Medical Center (US), The University of Texas MD Anderson Cancer Center (US), Harvard University (US), Vardhman Mahavir Medical College & Safdarjung Hospital (IN), Medical College of Wisconsin (US), Centre Hospitalier Universitaire de Sherbrooke (CA), Yale University (US), University of Illinois Chicago (US), University of Chicago (US), Universal Scientific Education and Research Network (IR), Donald & Barbara Zucker School of Medicine at Hofstra/Northwell (US), Dana-Farber Cancer Institute (US), Loxo Oncology at Lilly (United States) (US), Methodist Dallas Medical Center (US), Dana-Farber Brigham Cancer Center (US), Children's Specialized Hospital (US), Cooper Union (US), The University of Texas Health Science Center at Houston (US), University of Cincinnati Medical Center (US)
Openalex Percentile: Top 52%
Chemotherapy-induced organ toxicity mitigation
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.